Dupilumab therapy rapidly improved alopecia areata associated with trichotillomania in an atopic dermatitis patient

Dear Editor, Alopecia can occur as a serious complication of atopic dermatitis (AD). Dupilumab, an interleukin (IL)-4 receptor subunit alpha antagonist that down regulates T-helper 2 responses, has recently been approved as a treatment for AD. It has subsequently been reported that dupilumab amelior...

Full description

Saved in:
Bibliographic Details
Published inAllergology International Vol. 69; no. 3; pp. 480 - 482
Main Authors Manaka Ushida, Akifumi Ohshita, Yukiyasu Arakawa, Fuminao Kanehisa, Norito Katoh, Jun Asai
Format Journal Article
LanguageJapanese
Published JAPANESE SOCIETY OF ALLERGOLOGY 01.07.2020
Online AccessGet full text

Cover

More Information
Summary:Dear Editor, Alopecia can occur as a serious complication of atopic dermatitis (AD). Dupilumab, an interleukin (IL)-4 receptor subunit alpha antagonist that down regulates T-helper 2 responses, has recently been approved as a treatment for AD. It has subsequently been reported that dupilumab ameliorated alopecia areata (AA) in AD patients in a number of cases. However, in AD patients hair loss can be caused by trichotillomania as well as AA. Here, we report a case in which AA complicated with trichotillomania in an AD patient was rapidly ameliorated by dupilumab. A 33-year-old female presented with severe AD. A physical examination revealed erythema, scaling and lichenification over her entire body (Eczema Area and Severity Index [EASI] score: 46) and multiple alopecia patches on her scalp, which had first appeared 6 months prior to her visit.
ISSN:1323-8930